The latest news in France before distribution of third-generation pneumococcal conjugate vaccines

IF 2.9 4区医学 Q2 INFECTIOUS DISEASES

Infectious diseases now Pub Date : 2024-06-13 DOI:10.1016/j.idnow.2024.104937

Robert Cohen , Corinne Levy , Emmanuelle Varon

{"title":"The latest news in France before distribution of third-generation pneumococcal conjugate vaccines","authors":"Robert Cohen , Corinne Levy , Emmanuelle Varon","doi":"10.1016/j.idnow.2024.104937","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>In 2023 in France, 15 valent- pneumococcal conjugate vaccines (PCV15) have been recommended as alternatives to PCV13 for children < 2 years. PCV20 has been recommended for at-risk adults but not yet for infants, while PCV21 targets older adults. We endeavored to estimate the potential benefit of new pneumococcal vaccines in preventing invasive pneumococcal infections by comparing serotype extension to PCV13.</p></div><div><h3>Patients and methods</h3><p>The National Reference Centre for Pneumococci distributed <em>S. pneumoniae</em> IPD serotypes from children and adults.</p></div><div><h3>Results</h3><p>In 2022, for children under 24 months, PCV15 and PCV20 ensured 10 % and 36 % more coverage against IPD than PCV13. For adults, PCV15, PCV20, and PCV21 covered up to 3 %, 26 %, and 50 % more IPD cases than PCV13.</p></div><div><h3>Conclusion</h3><p>The new generation of pneumococcal vaccines could reduce the burden of invasive pneumococcal infections through serotype extension. Additional studies are needed in parallel to optimize their utilization and improve vaccine coverage in France.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104937"},"PeriodicalIF":2.9000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001040/pdfft?md5=d3292318b7a1e75f184fa58a2870394d&pid=1-s2.0-S2666991924001040-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991924001040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In 2023 in France, 15 valent- pneumococcal conjugate vaccines (PCV15) have been recommended as alternatives to PCV13 for children < 2 years. PCV20 has been recommended for at-risk adults but not yet for infants, while PCV21 targets older adults. We endeavored to estimate the potential benefit of new pneumococcal vaccines in preventing invasive pneumococcal infections by comparing serotype extension to PCV13.

Patients and methods

The National Reference Centre for Pneumococci distributed S. pneumoniae IPD serotypes from children and adults.

Results

In 2022, for children under 24 months, PCV15 and PCV20 ensured 10 % and 36 % more coverage against IPD than PCV13. For adults, PCV15, PCV20, and PCV21 covered up to 3 %, 26 %, and 50 % more IPD cases than PCV13.

Conclusion

The new generation of pneumococcal vaccines could reduce the burden of invasive pneumococcal infections through serotype extension. Additional studies are needed in parallel to optimize their utilization and improve vaccine coverage in France.

查看原文本刊更多论文

法国在分发第三代肺炎球菌结合疫苗之前的最新消息。

简介：2023 年，法国建议儿童接种 15 价肺炎球菌结合疫苗 (PCV15) 以替代 PCV13：国家肺炎球菌参考资料中心分发了来自儿童和成人的肺炎球菌 IPD 血清型：2022 年，对于 24 个月以下的儿童，PCV15 和 PCV20 的 IPD 疫苗覆盖率分别比 PCV13 高出 10% 和 36%。对于成人，PCV15、PCV20 和 PCV21 对 IPD 病例的覆盖率分别比 PCV13 高出 3%、26% 和 50%：结论：新一代肺炎球菌疫苗可通过扩展血清型来减少侵袭性肺炎球菌感染的负担。同时还需要开展更多的研究，以优化疫苗的使用并提高疫苗在法国的覆盖率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious diseases now Medicine-Infectious Diseases

CiteScore

7.10

自引率

2.90%

发文量

116

审稿时长

40 days